Quidel

Raritan, NJ · Owned · N/A · 569,000 · Administrative offices, R&D and manufacturing

Rochester, NY (513 Technology Blvd) · Owned · N/A · 438,628 · Manufacturing

San Diego, CA (Summers Ridge) · Leased · 2033 - options to extend for two additional 5-year periods · 316,531 · Administrative offices, sales and marketing, R&D and manufacturing (principal executive offices)

Rochester, NY (100 Indigo Creek) · Owned · N/A · 260,221 · Office, R&D

Pencoed, Wales (1) · Owned · N/A · 198,380 · Office, manufacturing

Athens, OH · Leased · 2027 · 149,240 · Administrative offices, sales and marketing, R&D and manufacturing

Carlsbad, CA (Rutherford) · Leased · 2036 - options to extend for two additional 5-year periods · 128,745 · Manufacturing

Memphis, TN · Leased · 2026 · 116,500 · Warehouse

San Diego, CA (Waples Ct.) · Leased · 2031 - options to extend for two additional 5-year periods · 106,412 · Office, light manufacturing, storage, packaging, assembly and distribution

Rochester, NY (130 Indigo Creek) · Owned · N/A · 103,138 · Office, R&D

Strasbourg, France · Owned · N/A · 97,951 · Warehouse, service

Rochester, NY (1000 Lee Road) · Leased · 2027 · 89,114 · Manufacturing

Pompano Beach, FL · Owned · N/A · 21,500 · Manufacturing

(1) In December 2024, the Company entered into an agreement for the expansion of the office building and manufacturing facility, which is expected to be complete and fully operational in early 2027.

We believe that our facilities are adequate for our current needs, and we currently do not anticipate any material difficulty in renewing any of our leases as they expire or securing additional or replacement facilities, in each case, on commercially reasonable terms. However, in anticipation of our growth strategy, we may pursue additional facilities.

• Ortho-Clinical Diagnostics Denmark, filial af Ortho-Clinical Diagnostics Netherlands B.V. Denmark⁸
• Ortho-Clinical Diagnostics Egypt Investment LLC Egypt⁸
• Ortho-Clinical Diagnostics Egypt Services LLC Egypt⁸
• Ortho-Clinical Diagnostics Egypt for Trading & Importation LLC Egypt⁸
• Ortho-Clinical Diagnostics FinCo S.à r.l. Luxembourg⁸
• Ortho-Clinical Diagnostics FinCo S.à r.l. (Barbados branch) Barbados⁸
• Ortho-Clinical Diagnostics FinCo S.à r.l. (US branch) New York, United States⁸
• Ortho-Clinical Diagnostics France SAS France⁸
• Ortho-Clinical Diagnostics GmbH Germany⁸
• Ortho-Clinical Diagnostics GmbH (Austria branch) Austria⁸
• Ortho-Clinical Diagnostics GmbH (Swiss branch) Switzerland⁸
• Ortho-Clinical Diagnostics Holdings Luxembourg S.à r.l. Luxembourg⁸
• Ortho-Clinical Diagnostics Italy S.r.l. Italy⁸
• Ortho-Clinical Diagnostics K.K. Japan⁸
• Ortho-Clinical Diagnostics Limited Liability Company Russia⁸
• Ortho-Clinical Diagnostics Luxembourg S.à r.l. Luxembourg⁸
• Ortho-Clinical Diagnostics Medical Technology (Changsha) Co., Ltd. China⁸
• Ortho-Clinical Diagnostics Mexico Operations S. de R.L. de C.V. Mexico⁸
• Ortho-Clinical Diagnostics Mexico Services S. de R.L. de C.V. Mexico⁸
• Ortho-Clinical Diagnostics NV Belgium⁸
• Ortho-Clinical Diagnostics NV (Dutch branch) Netherlands⁸
• Ortho-Clinical Diagnostics Netherlands B.V. Netherlands⁸
• Ortho-Clinical Diagnostics Netherlands BV (Puerto Rico branch) Puerto Rico⁸
• Ortho-Clinical Diagnostics Norway (branch of Ortho-Clinical Diagnostics Netherlands B.V.) Norway⁸
• Ortho-Clinical Diagnostics Panama Export S.A. Panama⁸
• Ortho-Clinical Diagnostics Panama S.A. Panama⁸
• Ortho-Clinical Diagnostics Philippines Inc. Philippines⁸
• Ortho-Clinical Diagnostics S.à r.l. Luxembourg⁸
• Ortho-Clinical Diagnostics Singapore Pte. Ltd. Singapore⁸
• Ortho-Clinical Diagnostics Singapore Pte. Ltd. (Korea branch) South Korea⁸
• Ortho-Clinical Diagnostics Spain, S.L. Spain⁸
• Ortho-Clinical Diagnostics Sweden AB Sweden⁸
• Ortho-Clinical Diagnostics Switzerland GmbH Switzerland⁸
• Ortho-Clinical Diagnostics Trading (China) Co. Ltd. China⁸
• Ortho-Clinical Diagnostics Trading (China) Co. Ltd. (Beijing branch) China⁸
• Ortho-Clinical Diagnostics Trading (China) Co. Ltd. (Hangzhou branch) China⁸
• Ortho-Clinical Diagnostics U.S. FinanceCo I, LLC Delaware, United States⁸
• Ortho-Clinical Diagnostics, Inc. New York, United States⁸
• Quidel Cardiovascular Inc. Delaware, United States⁸
• Quidel Corporation Delaware, United States⁸
• Quidel Diagnostics India Private Limited India⁸
• Quidel France SARL France⁸
• Quidel Germany, GmbH Germany⁸
• Quidel Hong Kong, Ltd. Hong Kong⁸
• Quidel International, LLC Delaware, United States⁸
• Quidel Ireland Limited Ireland⁸
• Quidel Italy SRL Italy⁸
• Quidel Services, LLC Delaware, United States⁸
• QuidelOrtho Canada Corporation Canada⁸
• QuidelOrtho Health Operational Services Limited Company Turkey⁸
• QuidelOrtho Regional Headquarters Company Saudi Arabia⁸
• QuidelOrtho Sales Company, LLC Delaware, United States⁸

• The healthcare industry and related industries that we serve have undergone, and are in the process of undergoing, significant changes, including staffing constraints and efforts to reduce costs, which could adversely affect our business, financial condition and results of operations.
• Consolidation of our customer base, the formation of group purchasing organizations and government-sponsored tendering processes could materially adversely affect our sales and results of operations.
• We may engage in strategic transactions, including acquisitions, investments, joint ventures, licensing arrangements and other strategic relationships, undertake strategic restructurings or divest, spin-off or discontinue certain business operations, and may not successfully identify or consummate these strategic transactions; therefore, we may not realize the anticipated benefits of these transactions, if any.
• We have been incorporating AI into our internal operations and may incorporate AI into our products and services. Implementation of AI and machine learning technologies may result in legal and regulatory risks, reputational harm or have other adverse consequences to our business.
• Risks Relating to Our International Operations
• As a global business, we face risks relating to our non-U.S. operations and international sales, including inherent macroeconomic, geopolitical and regulatory risks, that could impact our financial performance, cause interruptions in our current business operations and impede our growth strategy.
• Currency translation risk and currency transaction risk may adversely affect our financial condition, results of operations and cash flows.
• Risks Relating to Our IT Systems
• Our ability, or that of our providers or third-party collaboration partners, to protect our information systems in our IT and product systems, and personal and confidential information, including from data corruption, cyber-attacks, security breaches or IT errors, is critical to the success of our business.
• Interruptions to our third-party IT service providers and/or the inability of our digital solutions to interoperate with certain operating systems could impair the delivery of our cloud-based solutions and negatively impact our business.
• Risks Relating to Our Intellectual Property
• To remain competitive, we must continue to develop, obtain and protect proprietary technology rights; otherwise, we may lose market share or need to reduce prices as a result of competitors selling lower priced or technologically superior products or services that compete with ours.
• Intellectual property risks, third-party claims of infringement, misappropriation or violation of proprietary rights and other claims against us could adversely affect our ability to market our products and services, require us to redesign our products or services or attempt to seek licenses from third parties, and materially adversely affect our operating results. In addition, the defense of such claims could result in significant costs and divert the attention of our management and other key employees.
• Risks Relating to Government Regulation
• Regulation of Our Industry and Products
• Some of our respiratory products were authorized by the FDA through an EUA and the loss of such authorization could have a material adverse effect on our business, results of operations, financial position and cash flows.
• If we are unable to obtain or maintain required clearances or approvals for the commercialization of our products in the U.S. and certain foreign countries where we intend to sell our products, we will not be able to sell those products in such jurisdictions, which could negatively impact our results of operations.
• If the results of clinical studies required to gain regulatory approval to sell our products are not available when expected, or do not demonstrate the safety and effectiveness of those products, we may be unable to obtain regulatory approval and sell those products.
• Disruptions at the FDA and other government agencies, including disruptions caused by funding shortages or statutory, regulatory or policy changes, could hinder their ability to hire, retain or deploy key leadership and other personnel, prevent them from performing normal business functions on which the operation of our business may rely, or otherwise prevent new or modified products from being developed, cleared, approved or commercialized in a timely manner or at all, which could negatively impact our business.
• We may encounter challenges entering into contracts with government entities due to government-sponsored tendering requirements, and any contracts that we have entered into or will enter into with government entities may involve future funding, compliance and penalties risks.
• If one or more of our products is claimed to be defective or does not comply with applicable regulations, we could be subject to claims of liability and harm to our reputation that could adversely affect our business.
• We are subject to healthcare laws and regulations that could result in liability, require us to change our business practices and restrict our operations in the future.
• Certain Other Regulations Relating to Our Business
• We use hazardous materials in our business that may result in substantial compliance costs or claims against us relating to handling, storage or disposal.
• We are exposed to significant risks in relation to compliance with anti-bribery and anti-corruption laws and regulations and economic sanctions programs.
• Our collection, use and disclosure of personal information, including health information, and confidential information is subject to federal and state privacy, data security and data protection regulations, as well as privacy, data security and data protection laws outside the U.S., including in the EEA, the U.K. and China, and our failure to comply with those laws and regulations or to adequately secure this information could result in significant liability or reputational harm.
• We are subject to U.S. and foreign tax laws, and changes to such tax laws or differing interpretation of those laws by the relevant governmental authorities could adversely affect us.
• Risks Relating to Corporate Finance
• We may need to raise additional funds to finance our future capital or operating needs or other business purposes, which could have adverse consequences on the interests of our stockholders, and may not be available on acceptable terms or at all.
• Our indebtedness could adversely affect our financial condition, limit our ability to raise additional capital to fund our operations and prevent us from fulfilling our obligations under our indebtedness.
• We may not be able to generate sufficient cash flows from operating activities to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful.
• The terms of the Credit Agreement impose restrictions that may limit our current and future operating flexibility, particularly our ability to respond to changes in the economy or our industry or to take certain actions, which could harm our long-term interests and may limit our ability to make payments on our indebtedness.
• Risks Relating to Our Employees
• We may have difficulty attracting, motivating and retaining executives and other key employees.
• If we are required to make unexpected payments to any defined benefit plans or other post-employment benefit plans (“Benefit Plans”) applicable to our employees, our financial condition may be adversely affected.
• We are subject to work stoppages, union negotiations, labor disputes and other matters associated with our labor force, which may adversely impact our operations and cause us to incur incremental costs.
• General Risk Factors
• We are subject to, and may in the future become subject to, disputes, claims and litigation that could result in significant expenses and could ultimately result in an unfavorable outcome for us.
• Expectations of our performance related to sustainability matters, or the reporting of such matters, may impose additional costs on us and expose us to new risks.
• We are exposed to business risk which, if not fully covered by insurance, could have an adverse effect on our results of operations.
• Some provisions of our Charter, our Bylaws and Delaware law may make takeover attempts difficult, which could depress the price of our common stock and inhibit our stockholders’ ability to receive a premium price for their shares.
• Our Bylaws designate the Court of Chancery of the State of Delaware (the “Court of Chancery”) as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.
• The market price of our common stock may be volatile.
• Future sales of our common stock by us or our stockholders in the public market, or the perception that such sales may occur, could reduce the price of our common stock, and any additional capital raised by us through the sale of equity or convertible securities may dilute ownership in the Company.
• If we fail to develop or maintain an effective system of internal controls, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial reporting, which would harm our business and the trading price of our common stock.